These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 7722243

  • 1. [Vitreoretinal proliferation. II. Pathogenic hypotheses].
    Baudouin C, Gastaud P.
    J Fr Ophtalmol; 1994; 17(12):800-11. PubMed ID: 7722243
    [Abstract] [Full Text] [Related]

  • 2. [Vitreoretinal proliferation. I. Clinicopathological aspects].
    Baudouin C, Gastaud P.
    J Fr Ophtalmol; 1994; 17(12):789-99. PubMed ID: 7722242
    [Abstract] [Full Text] [Related]

  • 3. EIU in the rat promotes the potential of syngeneic retinal cells injected into the vitreous cavity to induce PVR.
    Behar-Cohen FF, Thillaye-Goldenberg B, de Bizemont T, Savoldelli M, Chauvaud D, de Kozak Y.
    Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3915-24. PubMed ID: 11053294
    [Abstract] [Full Text] [Related]

  • 4. [Immunomorphological study of the vitreous body and subretinal fluid in vitreoretinal proliferation].
    Baudouin C, Brignole F, Bayle J, Fredj-Reygrobellet D, Lapalus P, Gastaud P.
    J Fr Ophtalmol; 1991 Nov; 14(3):147-52. PubMed ID: 1918821
    [Abstract] [Full Text] [Related]

  • 5. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
    Dieudonné SC, La Heij EC, Diederen RM, Kessels AG, Liem AT, Kijlstra A, Hendrikse F.
    Ophthalmic Res; 2007 Nov; 39(3):148-54. PubMed ID: 17534114
    [Abstract] [Full Text] [Related]

  • 6. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
    Limb GA, Chignell AH, Cole CJ, Green WT, Webster L, Hollifield RD, Dumonde DC.
    Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
    [Abstract] [Full Text] [Related]

  • 7. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.
    Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ.
    Am J Ophthalmol; 2004 Jun; 137(6):1105-15. PubMed ID: 15183797
    [Abstract] [Full Text] [Related]

  • 8. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis.
    Esser P, Heimann K, Bartz-schmidt KU, Fontana A, Schraermeyer U, Thumann G, Weller M.
    Exp Eye Res; 1997 Sep; 65(3):365-78. PubMed ID: 9299173
    [Abstract] [Full Text] [Related]

  • 9. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
    Kon CH, Occleston NL, Aylward GW, Khaw PT.
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
    [Abstract] [Full Text] [Related]

  • 10. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
    Liou GI, Pakalnis VA, Matragoon S, Samuel S, Behzadian MA, Baker J, Khalil IE, Roon P, Caldwell RB, Hunt RC, Marcus DM.
    Mol Vis; 2002 Dec 20; 8():494-501. PubMed ID: 12500176
    [Abstract] [Full Text] [Related]

  • 11. [Stages of cell proliferation in an experimental model of vitreoretinal proliferation following injection of platelet-rich plasma].
    Pisella PJ, Baudouin C.
    J Fr Ophtalmol; 1996 Dec 20; 19(10):576-84. PubMed ID: 8959097
    [Abstract] [Full Text] [Related]

  • 12. Soluble TNF receptors in vitreoretinal proliferative disease.
    Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH.
    Invest Ophthalmol Vis Sci; 2001 Jun 20; 42(7):1586-91. PubMed ID: 11381065
    [Abstract] [Full Text] [Related]

  • 13. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy.
    Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT.
    Invest Ophthalmol Vis Sci; 1998 Jul 20; 39(8):1524-9. PubMed ID: 9660504
    [Abstract] [Full Text] [Related]

  • 14. [Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis].
    Rouberol F, Chiquet C.
    J Fr Ophtalmol; 2014 Sep 20; 37(7):557-65. PubMed ID: 24997864
    [Abstract] [Full Text] [Related]

  • 15. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
    Mandava N, Blackburn P, Paul DB, Wilson MW, Read SB, Alspaugh E, Tritz R, Barber JR, Robbins JM, Kruse CA.
    Invest Ophthalmol Vis Sci; 2002 Oct 20; 43(10):3338-48. PubMed ID: 12356843
    [Abstract] [Full Text] [Related]

  • 16. Simple retinal detachments: identifying the at-risk case.
    Asaria RH, Gregor ZJ.
    Eye (Lond); 2002 Jul 20; 16(4):404-10. PubMed ID: 12101447
    [Abstract] [Full Text] [Related]

  • 17. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
    Roldán-Pallarés M, Rollín R, Mediero A, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R.
    Mol Vis; 2005 Jul 07; 11():461-71. PubMed ID: 16030497
    [Abstract] [Full Text] [Related]

  • 18. Active scatter factor (HGF/SF) in proliferative vitreoretinal disease.
    Briggs MC, Grierson I, Hiscott P, Hunt JA.
    Invest Ophthalmol Vis Sci; 2000 Sep 07; 41(10):3085-94. PubMed ID: 10967068
    [Abstract] [Full Text] [Related]

  • 19. Anterior proliferative vitreoretinopathy in trauma and complicated retinal detachment. A histopathologic study.
    Mietz H, Kirchhof B, Heimann K.
    Ger J Ophthalmol; 1994 Jan 07; 3(1):15-8. PubMed ID: 8142875
    [Abstract] [Full Text] [Related]

  • 20. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy.
    Dieudonné SC, La Heij EC, Diederen R, Kessels AG, Liem AT, Kijlstra A, Hendrikse F.
    Invest Ophthalmol Vis Sci; 2004 Nov 07; 45(11):4113-8. PubMed ID: 15505063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.